Clinical Trial

SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 31, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an open label, single arm, phase 2 trial investigating bezuclastinib plus sunitinib in patients with GIST who have previously progressed on sunitinib.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-01-05; most recent amendment 2025-10-29.
Status change: Recruiting → Active, Not Recruiting 2025-10-29
Status change: Not Yet Recruiting → Recruiting 2024-06-21
Trial Details
NCT Number NCT06208748
Lead Sponsor Sarcoma Alliance for Research through Collaboration
Collaborators: Cogent Biosciences, Inc., Dana-Farber Cancer Institute, The Life Raft Group
Conditions Gastrointestinal Stromal Tumors, GIST
Enrollment 40 participants
Start Date 2024-08-01
Primary Completion 2026-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2025-10-31